Welcome to our dedicated page for Bowen Acquisition SEC filings (Ticker: BOWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waiting for a SPAC’s merger news can feel like tracking a moving target—especially when each 8-K drops pages of legal language on trust redemptions and sponsor warrants. Bowen Acquisition Corp’s disclosures fit that pattern, and digging out the details that move BOWN’s share price is time-consuming.
Our platform solves that problem. Stock Titan’s AI reads every new document the moment it hits EDGAR, from Bowen Acquisition Corp insider trading Form 4 transactions to the dense business-combination proxy. You’ll see real-time alerts and plain-English summaries that turn a fifty-page 8-K into a five-minute briefing. Prefer original text? The full filings sit a click away, already indexed and searchable.
Use the page to:
- Follow Bowen Acquisition Corp quarterly earnings report 10-Q filing cash-burn trends without poring over balance sheets.
- Track Bowen Acquisition Corp Form 4 insider transactions real-time to gauge sponsor confidence.
- Get Bowen Acquisition Corp SEC filings explained simply—AI highlights merger milestones, redemption ratios, and warrant adjustments.
- Dive into Bowen Acquisition Corp earnings report filing analysis or the Bowen Acquisition Corp annual report 10-K simplified for trust asset breakdowns.
If you’re asking “How do I understand Bowen Acquisition Corp SEC documents with AI?” or searching for “Bowen Acquisition Corp proxy statement executive compensation,” this hub has you covered. Each 8-K material event is labeled and cross-linked, letting you move from headline to source in seconds. Whether you need Bowen Acquisition Corp executive stock transactions Form 4 or Bowen Acquisition Corp 8-K material events explained, the information arrives faster—and clearer—than ever before.
Bowen Acquisition Corp (BOWN) is calling an extraordinary general meeting on December 12, 2025 for shareholders to vote on extending the deadline to complete its initial business combination. The Extension Proposal would allow the board to push the current termination date from December 14, 2025 by up to six one‑month increments, to as late as June 14, 2026. A separate Adjournment Proposal would let the board adjourn the meeting if more time is needed to secure approval.
Bowen has a signed deal with Shenzhen Qianzhi BioTechnology Co. Ltd., which shareholders approved in January 2025 but has not yet closed. Public shareholders may elect to redeem their shares for cash; based on about $8.26 million in the trust as of November 20, 2025, the company estimates a redemption price of roughly $11.35 per share. If the Extension Proposal fails and no deal closes by December 14, 2025, Bowen would redeem all public shares and liquidate. Shareholders who do not redeem now, and did not redeem at the earlier Qianzhi vote, will not have redemption rights when that business combination is completed.
Bowen Acquisition Corp. (BOWN) filed a Form 12b-25 (NT 10-Q) to notify a delayed filing of its Quarterly Report for the period ended September 30, 2025. The company states it cannot file within the prescribed time without unreasonable effort and expense.
Bowen cites the need for additional time to compile and process required information because it does not have full-time accounting and administrative staff. It also notes it has been in the process of seeking to consummate its initial business combination, which adds to the timing constraints.
Bowen Acquisition Corp (BOWN) calls a shareholder vote to extend its SPAC deadline. The extraordinary general meeting is set for 10:00 a.m. ET on December 12, 2025, to approve an amendment allowing up to six one‑month extensions, moving the current termination date from December 14, 2025 to as late as June 14, 2026. A separate proposal would permit adjournment if more time is needed to effect the extension.
Public shareholders may elect to redeem their shares for cash from the trust by submitting shares to the transfer agent by 5:00 p.m. ET on December 10, 2025. The company notes shareholders had already approved its business combination with Shenzhen Qianzhi BioTechnology in January 2025, but closing remains pending. If the extension fails and no deal closes by December 14, 2025, Bowen will redeem public shares and liquidate per its charter.
As of the record date November 12, 2025, 2,994,371 ordinary shares were outstanding, including 727,871 public shares. Sponsors and insiders hold 2,066,782 shares (approximately 69%) and intend to vote in favor.
Bowen Acquisition Corp. (BOWN) reported a Nasdaq delisting decision. Nasdaq notified the company on
After an appeal and hearing on
FAQ
What is the current stock price of Bowen Acquisition (BOWN)?
What is the market cap of Bowen Acquisition (BOWN)?
